{"id":"W3202278757","doi":"10.1016/j.annonc.2021.08.550","title":"267P Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) + entinostat (entino) in MORPHEUS-HR+ breast cancer (M-HR+BC)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Oncology; Breast cancer; Internal medicine; Cancer; Cancer research; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003298355,0.0002861094,0.002071631,0.0004143542,0.00008913295,0.00002069779,0.0002330321,0.0002413785,0.02095235],"category_scores_gemma":[0.001104588,0.0002333925,0.0003049336,0.000883316,0.0003116721,0.0002469197,0.00025374,0.0003043137,0.00003517389],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001456484,"about_ca_system_score_gemma":0.002176812,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001031484,"about_ca_topic_score_gemma":0.003051712,"domain_scores_codex":[0.9956164,0.001149897,0.001561582,0.0005396923,0.000680818,0.0004515719],"domain_scores_gemma":[0.9956501,0.0004160448,0.0008829227,0.0004741824,0.002375297,0.0002015063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3068058,0.03592882,0.00140942,0.001013667,0.004419047,0.002875828,0.004459337,0.0004106775,0.3061222,0.0009096888,0.05140064,0.284245],"study_design_scores_gemma":[0.7777129,0.002778343,0.002814083,0.001761571,0.00199474,0.0007219831,0.001078038,0.01001773,0.1920576,0.0009206771,0.007615043,0.0005273438],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9784006,0.0009007666,0.0000371157,0.01258781,0.0001391444,0.00102835,0.0003754931,0.00002314081,0.006507531],"genre_scores_gemma":[0.9903782,0.001168898,0.0003498361,0.002928896,0.0001387389,0.0002135175,0.0004912231,0.00002991483,0.004300755],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4709071,"threshold_uncertainty_score":0.9799426,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.198666828918969,"score_gpt":0.4921568923871596,"score_spread":0.2934900634681906,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}